342577-38-2
Chemical Structure
Velneperit
Synonym(s): S2367
- CAS No.: 342577-38-2
- Formula:C17H24F3N3O3S
- Molecular Weight:407.45
IUPAC Name: (1r,4r)-4-((1,1-dimethylethyl)sulfonamido)-N-(5-(trifluoromethyl)pyridin-2-yl)cyclohexane-1-carboxamide
InChIKey: WGEWUYACXPEFPO-AULYBMBSSA-N
SMILES: FC(F)(F)C1=CN=C(NC([C@H]2CC[C@H](NS(=O)(C(C)(C)C)=O)CC2)=O)C=C1
Biological Activity: Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Velneperit | 98.25% | Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ishihara A, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7154-8. [Content Brief]
- [2]. McCullough KM, et al. Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction. Transl Psychiatry. 2018 Aug 22;8(1):164. [Content Brief]
- [3]. Powell, A. G., C. M. Apovian, and L. J. Aronne. New drug targets for the treatment of obesity. Clinical pharmacology & therapeutics 90.1 (2011): 40-51.
Keywords
